AKT1 and hepatocellular carcinoma: Everolimus failed to show improved overall survival in patients with advanced HCC who were resistant or intolerant to sorafenib, possibly due to everolimus-induced feedback activation of AKT following selective mTORC1 complex inhibition [15].